Biomica CEO to Participate in Panel Discussion at 7th European Annual Microbiome Movement
Biomica Ltd., a clinical-stage biopharmaceutical company and a subsidiary of Evogene (NASDAQ: EVGN), announced that its CEO Dr. Elran Haber and VP R&D Dr. Shiri Meshner will attend the 7th Annual Microbiome Movement Drug Development Europe in London from January 31 to February 2, 2023. Dr. Haber will participate in two panel discussions, focusing on translating microbiome science into products and investor collaboration. Dr. Meshner's presentation, entitled Rationally Designed LBPs – From Computational & Pre-clinical Data to Clinical Studies, is scheduled for February 1, 2023. Both executives are available for one-on-one meetings at the conference.
- None.
- None.
REHOVOT, Israel, Jan. 24, 2023 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced its CEO and VP R&D will both be participating in 7th Annual Microbiome Movement Drug Development Europe, taking place in London, UK, between January 31 and February 2, 2023.
The 7th Microbiome Movement – Drug Development Summit Europe aims to unite Europe's leading drug developers and microbiome experts to share their latest discoveries on microbiome functionality, translation, clinical development, biomarker discovery and manufacturing scale-up. In attendance from Biomica will be CEO Dr. Elran Haber and VP R&D Dr. Shiri Meshner.
Dr. Haber will take part in two industry panel discussions. These are entitled, "How to Turn Outstanding Microbiome Science into Effective & Efficient Products", taking place on February 1, 2023, at 9:30am GMT and "Working with Microbiome Investors", scheduled to take place later that day at 4:30pm GMT.
Dr. Meshner will be presenting on February 1, 2023, at 2:55pm, and the presentation is entitled, "Rationally Designed LBPs – From Computational & Pre-clinical Data to Clinical Studies."
Dr. Haber and Dr. Meshner will both be available for one-on-one meetings at the conference, and those interested should be in touch with the investor or public relations team.
About Biomica
Biomica is a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN). For more information, please visit www.biomicamed.com.
Logo - https://mma.prnewswire.com/media/1974949/Biomica.jpg
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
Evogene Contacts:
Investor Relations
Kenny Green
Email: kenny.green@evogene.com
Tel: +1 212 378 8040
Public Relations:
Lital Mamon
Email: lital.mamon@evogene.com
Tel: +972 8 931 2097
View original content:https://www.prnewswire.com/news-releases/biomica-ceo-to-participate-in-panel-discussion-at-7th-european-annual-microbiome-movement-301729122.html
SOURCE Biomica Ltd.
FAQ
What are the details of the Biomica participation at the Microbiome Movement event in 2023?
When will Dr. Elran Haber speak at the conference?
What is Dr. Shiri Meshner's presentation topic at the event?
What is the goal of the Microbiome Movement summit?
Which company does Biomica belong to?
